Catching up with Merck in adjuvant melanoma, Bristol Myers burnishes Opdivo profile in earlier stages of cancer

Melanoma was the first cancer type for which Bristol Myers Squibb’s Opdivo scored an FDA approval. And the pharma giant is still trying to reach more patients with it.

In another step toward the broader goal of moving the PD-1 drug up the treatment lines, Bristol Myers announced that a trial testing Opdivo as an adjuvant treatment for patients with completely resected stage IIB/C melanoma met the primary endpoint of recurrence-free survival.

“Stage IIB/C melanoma patients are at high risk of disease recurrence, with approximately one third of stage IIB and half of stage IIC patients experiencing recurrence within five years after surgery,” said Gina Fusaro, development program lead, melanoma, in a statement.

Detailed results will be reserved for a future conference. They will likely be held up against what Merck posted for Keytruda, which was approved last year in the same setting.

In the trial, patients were either…
Click here to view original post

Be the first to comment

Leave a Reply

Your email address will not be published.


*